Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.
5-hydoxymethyl-2-furfural (5-
HMF) 的原药和衍
生物具有受保护或修饰的醛和/或醇分子。这些原药或衍
生物具有更高的
生物利用度,例如由于其在血液循环中的半衰期更长。因此,与 5-
HMF 相比,这些药物 i) 给药剂量更低和/或 ii) 给药次数更少,同时仍能保持 5-
HMF 的有益治疗效果。